Anxiety-like Behavior and GABAAR/BDZ Binding Site Response to Progesterone Withdrawal in a Stress-Vulnerable Strain, the Wistar Kyoto Rats.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Jun 2022
Historique:
received: 30 05 2022
revised: 16 06 2022
accepted: 19 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Stress susceptibility could play a role in developing premenstrual anxiety due to abnormalities in the hypothalamus-pituitary-adrenal (HPA) axis and impairments in the GABAA receptors' benzodiazepine (BDZ) site. Hence, we studied the stress-vulnerable Wistar Kyoto rat strain (WKY) to evaluate progesterone withdrawal (PW) effects on anxiety, HPA axis response, and to explore indicators of GABAA functionality in the BDZ site. For five days, ovariectomized WKY rats were administered 2.0 mg/kg of progesterone. Twenty-four hours after the last administration, rats were tested in the anxiety-like burying behavior test (BBT) or elevated plus maze test (EPM), and corticosterone was determined. [3H]Flunitrazepam binding autoradiography served as the BDZ binding site index of the GABAA receptor in amygdala nuclei and hippocampus's dentate gyrus (DG). Finally, different doses of diazepam in PW-WKY rats were tested in the BBT. PW induced anxiety-like behaviors in both BBT and EPM compared with No-PW rats. PW increased corticosterone, but was blunted when combined with PW and BBT. PW increased [3H]Flunitrazepam binding in the DG and central amygdala compared with No-PW rats. Diazepam at a low dose induced an anxiogenic-like response in PW rats, suggesting a paradoxical response to benzodiazepines. Overall, PW induced anxiety-like behavior, a blunted HPA axis response, and higher GABAAR/BZD binding site sensitivity in a stress-vulnerable rat strain. These findings demonstrate the role of stress-susceptibility in GABAAR functionality in a preclinical approximation of PMDD.

Identifiants

pubmed: 35806264
pii: ijms23137259
doi: 10.3390/ijms23137259
pmc: PMC9266311
pii:
doi:

Substances chimiques

Receptors, GABA-A 0
Progesterone 4G7DS2Q64Y
Flunitrazepam 620X0222FQ
Diazepam Q3JTX2Q7TU
Corticosterone W980KJ009P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Cámara de Diputados, inmujeres, proyecto de género
ID : NC-093380.1

Références

Eur J Endocrinol. 2000 Mar;142(3):269-73
pubmed: 10700721
Neurosci Biobehav Rev. 2005;29(4-5):525-46
pubmed: 15925696
J Neurosci. 2001 Jan 1;21(1):330-9
pubmed: 11150350
Pharmacol Biochem Behav. 2014 Jul;122:144-57
pubmed: 24727401
J Neuroendocrinol. 2018 Feb;30(2):
pubmed: 29072794
Psychiatry Res. 2015 Jan 30;231(1):64-70
pubmed: 25465316
Behav Brain Res. 2013 Sep 15;253:310-7
pubmed: 23872358
Psychopharmacology (Berl). 2016 Jun;233(11):2109-2117
pubmed: 26960697
Neuropsychopharmacology. 2006 Nov;31(11):2449-61
pubmed: 16710313
Gynecol Endocrinol. 2004 Feb;18(2):79-87
pubmed: 15195499
Acta Endocrinol (Copenh). 1993 Jun;128(6):536-42
pubmed: 8393259
J Clin Endocrinol Metab. 2003 Jul;88(7):3057-63
pubmed: 12843143
Int J Mol Sci. 2021 Feb 10;22(4):
pubmed: 33578758
Dev Psychobiol. 1999 Apr;34(3):227-34
pubmed: 10204098
J Clin Endocrinol Metab. 1990 Nov;71(5):1158-62
pubmed: 2172272
Psychoneuroendocrinology. 2017 Jan;75:83-90
pubmed: 27810707
Menopause Int. 2012 Jun;18(2):52-9
pubmed: 22611222
Prog Neurobiol. 2014 Feb;113:88-94
pubmed: 23978486
J Psychopharmacol. 2013 Dec;27(12):1180-5
pubmed: 23704364
Brain Res. 1995 Jun 26;684(1):112-4
pubmed: 7583199
Arch Fam Med. 1999 Mar-Apr;8(2):122-8
pubmed: 10101982
Nature. 1998 Apr 30;392(6679):926-30
pubmed: 9582073
Neuropharmacology. 2002 Sep;43(4):701-14
pubmed: 12367616
Brain Res. 2003 May 2;971(1):55-65
pubmed: 12691837
Eur J Pharmacol. 2003 Feb 28;463(1-3):145-61
pubmed: 12600707
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Nov;25(8):1615-28
pubmed: 11642658
Br J Pharmacol. 2017 Oct;174(19):3226-3241
pubmed: 28456011
Mol Pharmacol. 2003 Jan;63(1):53-64
pubmed: 12488536
Psychoneuroendocrinology. 2019 Nov;109:104372
pubmed: 31357135
Biomed Res Int. 2013;2013:868742
pubmed: 23533999
Pharmacol Biochem Behav. 1994 Apr;47(4):913-7
pubmed: 8029262
J Nerv Ment Dis. 2013 Sep;201(9):780-5
pubmed: 23995034
J Neurosci Methods. 1985 Aug;14(3):149-67
pubmed: 2864480
Behav Brain Res. 2002 Aug 21;134(1-2):175-83
pubmed: 12191804
Physiol Behav. 1996 Feb;59(2):369-73
pubmed: 8838618
Psychoneuroendocrinology. 2002 Apr;27(3):303-18
pubmed: 11818168
Front Behav Neurosci. 2018 Jul 03;12:127
pubmed: 30034327
J Ethnopharmacol. 2019 Sep 15;241:112006
pubmed: 31153863
J Psychopharmacol. 2012 Apr;26(4):543-54
pubmed: 21148026
Behav Pharmacol. 2011 Apr;22(2):136-46
pubmed: 21301323
Front Neuroendocrinol. 2020 Apr;57:100838
pubmed: 32268180
J Neurosci. 2012 Nov 28;32(48):17143-54
pubmed: 23197707
Psychosom Med. 2003 Sep-Oct;65(5):849-56
pubmed: 14508031
Pharmacol Biochem Behav. 2011 Oct;99(4):532-9
pubmed: 21672548
Health Psychol. 2007 Mar;26(2):201-13
pubmed: 17385972
Ann N Y Acad Sci. 2008 Dec;1148:64-73
pubmed: 19120092
Neuroscience. 1988 Jun;25(3):771-95
pubmed: 2841624
Stress. 2018 Sep;21(5):403-416
pubmed: 29764284
Compr Physiol. 2016 Mar 15;6(2):603-21
pubmed: 27065163
Pharmacol Biochem Behav. 1988 Jul;30(3):775-80
pubmed: 2905472
Brain Res. 1993 Dec 24;631(2):270-6
pubmed: 8131055
Pharmacol Biochem Behav. 2006 Jan;83(1):130-5
pubmed: 16483644
Horm Behav. 2014 Jan;65(1):6-13
pubmed: 24200620
Behav Brain Res. 2017 Jan 1;316:197-204
pubmed: 27596379
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Int J Environ Res Public Health. 2020 Feb 05;17(3):
pubmed: 32033286
Elife. 2016 Mar 14;5:e14120
pubmed: 26971710
Am J Physiol. 1994 Feb;266(2 Pt 2):R353-60
pubmed: 8141389
Pharmacol Biochem Behav. 1993 Dec;46(4):897-904
pubmed: 7906038
Iran Red Crescent Med J. 2011 Mar;13(3):199-202
pubmed: 22737463
Biol Mood Anxiety Disord. 2014 Feb 26;4(1):3
pubmed: 24572042
Biol Psychiatry. 2001 May 1;49(9):788-97
pubmed: 11331087
Psychoneuroendocrinology. 2004 Jul;29(6):767-77
pubmed: 15110926
Psychiatry Res. 1998 Nov 16;81(2):163-78
pubmed: 9858034
J Physiol Paris. 1993;87(4):229-38
pubmed: 8136789
Pharmacol Ther. 1990;46(3):321-40
pubmed: 2188266
Neuroscience. 2011 Sep 15;191:46-54
pubmed: 21600269
Eur J Endocrinol. 2003 May;148(5):571-7
pubmed: 12720542
Eur J Neurosci. 2001 Oct;14(7):1143-52
pubmed: 11683906
Arch Womens Ment Health. 2013 Apr;16(2):131-7
pubmed: 23329007
Pharmacol Biochem Behav. 1990 Sep;37(1):77-81
pubmed: 1979876
Physiol Behav. 1997 Sep;62(3):643-8
pubmed: 9272677
Psychosom Med. 1994 Sep-Oct;56(5):418-22
pubmed: 7809341
Neuroscience. 2016 Nov 12;336:123-132
pubmed: 27600948
Neuroscience. 2010 Oct 27;170(3):865-80
pubmed: 20670676
J Neurochem. 2000 Aug;75(2):732-40
pubmed: 10899949
Lancet. 2008 Apr 5;371(9619):1200-10
pubmed: 18395582
Cogn Affect Behav Neurosci. 2022 Jun;22(3):431-449
pubmed: 34873665
Curr Opin Neurobiol. 2012 Aug;22(4):717-23
pubmed: 22424846
Stress. 2015;18(2):160-8
pubmed: 25518868
Tohoku J Exp Med. 2013;230(3):151-4
pubmed: 23842447
Brain Res. 1995 May 22;680(1-2):135-41
pubmed: 7663969
Stress. 2019 Nov;22(6):640-646
pubmed: 31057066
Horm Behav. 2012 Sep;62(4):400-6
pubmed: 22814368

Auteurs

Dannia Islas-Preciado (D)

Lab de Neuropsicofarmacología, Dirección de Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México 14370, Mexico.

Gabriela Ugalde-Fuentes (G)

Lab de Neuropsicofarmacología, Dirección de Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México 14370, Mexico.

Isabel Sollozo-Dupont (I)

Lab de Neuropsicofarmacología, Dirección de Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México 14370, Mexico.

María Eva González Trujano (ME)

Lab de Neurofarmacología de Productos Naturales, Dirección de Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México 14370, Mexico.

Nancy Cervantes-Anaya (N)

Lab de Neuropsicofarmacología, Dirección de Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México 14370, Mexico.

Erika Estrada-Camarena (E)

Lab de Neuropsicofarmacología, Dirección de Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México 14370, Mexico.

Carolina López-Rubalcava (C)

Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados IPN (Cinvestav-IPN), Ciudad de México 07360, Mexico.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH